Factors associated with potential drug–drug interactions detected by Epocrates drug checker
| Variable | B | P value | 95% Cl |
| Epocrates total interactios | |||
| Gender (male/female) | 1.071 | 0.000 | 0.510 to 1.633 |
| Platelet | 0.004 | 0.037 | 0.000 to 0.008 |
| Erythrocyte sedimentation rate | −0.035 | 0.018 | −0.064 to −0.006 |
| C-reactive protein | 0.032 | 0.016 | 0.006 to 0.058 |
| Alkaline phosphatase | −0.018 | 0.002 | −0.029 to −0.007 |
| Diagnosis | −0.560 | 0.009 | −0.979 to −0.141 |
| Number of pharmacological/therapeutic subgroups (second level of ATC classification) | 2.161 | 0.000 | 1.956 to 2.366 |
| Hypnotics and sedatives | −0.631 | 0.033 | −1.211 to −0.050 |
| Antidepressants | −1.148 | 0.001 | −1.838 to −0.458 |
| Anticholinergic drugs | 2.266 | 0.000 | 1.544 to 2.987 |
| Analgesics | 1.632 | 0.017 | 0.295 to 2.969 |
| Statins | 2.641 | 0.000 | 1.705 to 3.576 |
| Antibiotic drugs | 0.934 | 0.034 | 0.073 to 1.795 |
| Antacids | 3.162 | 0.000 | 2.223 to 4.102 |
| Antihistamines | 1.898 | 0.003 | 0.640 to 3.157 |
| Bronchodilators | 2.937 | 0.000 | 1.728 to 4.146 |
| Nonsteroidal anti-inflammatory drugs (NSAIDS) | 0.785 | 0.037 | 0.049 to 1.520 |
| Laxatives | 1.993 | 0.000 | 1.045 to 2.941 |
| Thyroid disease therapy | 2.199 | 0.001 | 0.960 to 3.438 |
| Vitamins | 3.019 | 0.000 | 2.282 to 3.755 |
| Respiratory infection | 0.962 | 0.034 | 0.073 to 1.852 |
| Number of associated comorbidities | 1.575 | 0.000 | 0.911 to 2.240 |
| Heart attack | 1.754 | 0.006 | 0.501 to 3.007 |
| Cerebrovascular accident | 1.826 | 0.043 | 0.059 to 3.592 |
| Dementia | 3.377 | 0.000 | 1.720 to 5.034 |
| Rheumatic diseases | 2.736 | 0.000 | 1.262 to 4.210 |
| Liver disease | 1.990 | 0.009 | 0.497 to 3.482 |
| Diabetes mellitus | 2.764 | 0.000 | 1.668 to 3.860 |
| Renal failure | 3.223 | 0.000 | 1.789 to 4.657 |
| Number of interactions in which the route of the drug increased the manifestation of the interaction | 0.632 | 0.000 | 0.287 to 0.977 |
| Number of interactions in which the form of the drug increased the manifestation of the interaction | 0.625 | 0.000 | 0.296 to 0.955 |
| Number of interactions in which the dose of the drug increased the manifestation of the interaction R2=0.694; F (p)=34.918 (0.000)* | 1.328 | 0.000 | 0.761 to 1.894 |
| Contraindicated | |||
| Sodium | −0.007 | 0.024 | −0.124 to −0.001 |
| Antiepileptics drugs | −0.104 | 0.036 | −0.201 to −0.207 |
| Diuretics | −0.180 | 0.000 | −0.273 to −0.086 |
| Number of interactions in which the dose of the drug increased the manifestation of the interaction R2=0.112; F (p)=11.652 (0.000)* | 0.147 | 0.001 | 0.062 to 0.232 |
| Avoid – use alternative | |||
| Gender (male/female) | 0.341 | 0.003 | 0.116 to 0.565 |
| Uric acidi | 0.001 | 0.001 | 0.001 to 0.002 |
| Number of pharmacological/therapeutic subgroups (second level of ATC classification) | 0.160 | 0.000 | 0.092 to 0.229 |
| Length of hospitalisation (days) | 0.019 | 0.000 | 0.009 to 0.030 |
| Hypnotics and sedatives | −1.853 | 0.000 | −2.090 to −1.617 |
| Dopaminergic drugs | −1.359 | 0.001 | −2.161 to −0.558 |
| Nonsteroidal anti-inflammatory drugs (NSAIDS) | 0.515 | 0.001 | 0.206 to 0.825 |
| Statins | 0.451 | 0.011 | 0.105 to 0.797 |
| Cerebrovascular accident | 0.791 | 0.012 | 0.175 to 1.407 |
| Dementia | 0.808 | 0.013 | 0.171 to 1.444 |
| Rheumatic diseases | 0.647 | 0.028 | 0.071 to 1.224 |
| Liver disease | 0.616 | 0.035 | 0.042 to 1.189 |
| Diabetes mellitus | 0.399 | 0.037 | 0.023 to 0.774 |
| Number of interactions in which the route of the drug increased the manifestation of the interaction | 0.773 | 0.000 | 0.626 to 0.920 |
| Number of interactions in which the form of the drug increased the manifestation of the interaction | −0.382 | 0.000 | −0.519 to −0.244 |
| Number of interactions in which the dose of the drug increased the manifestation of the interaction R2=0.547; F (p)=33.345 (0.000)* | −0.296 | 0.034 | −0.570 to −0.022 |
*Statistically significant.
ATC, Anatomical Therapeutic Chemical; B, unstandardised coefficient; p, statistical significance.